Table 1. Baseline characteristics of study patients.
| Variables | Guideline-adherent (n = 45,595) | Non-adherent (n = 309,054) | P value |
|---|---|---|---|
| Age, years | 61.0 ± 15.5 | 72.9 ± 11.9 | <0.001 |
| Age > 65, n (%) | 19,665 (43.1) | 244,176 (79.0) | <0.001 |
| Age > 75, n (%) | 9,972 (21.9) | 155,066 (50.2) | <0.001 |
| Male gender, n (%) | 25,553 (56.0) | 170,918 (55.3) | 0.003 |
| Comorbidities, n (%) | |||
| Congestive heart failure | 14,615 (32.1) | 130,355 (42.2) | <0.001 |
| Hypertension | 20,607 (45.2) | 222,215 (71.9) | <0.001 |
| Diabetes mellitus | 8,005 (17.6) | 93,369 (30.2) | <0.001 |
| Previous stroke/TIA | 13,204 (29.0) | 110,465 (35.7) | <0.001 |
| Vascular disease | 7,479 (16.4) | 72,888 (23.6) | <0.001 |
| Hyperlipidemia | 9,114 (20.0) | 79,478 (25.7) | <0.001 |
| Chronic lung disease | 10,101 (22.2) | 115,792 (37.5) | <0.001 |
| Liver cirrhosis | 1,212 (2.7) | 10,663 (3.5) | <0.001 |
| ESRD | 368 (0.8) | 7,478 (2.4) | <0.001 |
| Malignancy | 2,013 (4.4) | 17,527 (5.7) | <0.001 |
| CHA2DS2-VASc score, median (IQR) | 2 (1–5) | 4 (3–6) | <0.001 |
| Use of anti-platelet agents, n (%) | 0 (0) | 135,488 (43.8) | < 0.001 |
AF = atrial fibrillation; ESRD = end-stage renal disease; IQR = interquartile range; TIA = transient ischemic attack.